One earnings story that caught my eye was this pharmaceutical name.
These major high-yield real estate investment trusts deserve a closer look.
Dividend Aristocrats possess durable competitive advantages, highly profitable business models, and long-term growth.
I'm going to play the part of a cockeyed optimist -- at least for a day.
These names pay dividends to shareholders and can raise them each year, even during recessions.
It's been quite a ride for the shares the past several years.
Amid a supportive environment these names have stable earnings and strong dividend yields.
Fundamental and micro strategists should be happy -- at least for the next few weeks.
The annual Triple Net Active Versus Passive Portfolio duel is rounding third, and headed for home.
The market is at an interesting juncture as the AI theme has been celebrated as a major economic shift.